Lantern Pharma Inc (LTRN) News

Starlight Therapeutics, a Subsidiary of Lantern Pharma Focused on CNS & Brain Cancers, Announces Dr. Marc Chamberlain as Chief Medical Officer

Starlight Therapeutics— a Lantern Pharma (Nasdaq: LTRN) subsidiary focused exclusively on the clinical...

Form 8-K - Current report

Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]

Form 4 - Statement of changes in beneficial ownership of securities

FDA Grants Lantern Pharma Orphan Drug Designation for Drug Candidate LP-284 in High-Grade B-cell Lymphomas (HGBL)

The Orphan Drug Designation strengthens LP-284’s clinical development path and can provide for additional market exclusivity and commercial...

Form 8-K - Current report

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

Lantern Pharma Reports Third Quarter 2023 Financial Results and Operational Highlights

Received IND clearance from FDA to initiate Phase 1 clinical trial for LP-284, a first-in-human trial for advanced, refractory non-Hodgkin’s...

Lantern Pharma to Report Third Quarter 2023 Operating & Financial Results on November 8th, 2023 at 4:30 p.m. ET

 Webcast to be held Wednesday, November 8th, 4:30 p.m. ET, register for the webcast here, or at the link provided below. Lantern Pharma Inc...

Form 8-K - Current report

Lantern Pharma to Present at the ThinkEquity Conference on October 19 at 1:30 p.m. ET

Lantern Pharma Inc. (NASDAQ: LTRN), an artificial intelligence (AI) company developing targeted and transformative cancer therapies using its...

Lantern Pharma Announces Publication in Clinical Cancer Research Highlighting the Enhanced Efficacy of LP-184 in Glioblastoma

Lantern Pharma Inc. (NASDAQ: LTRN), an artificial intelligence (AI) company developing targeted and transformative cancer therapies using its...

Lantern Pharma Announces First Patient Dosed in the Phase 1 Study for LP-184 in Advanced Solid Tumors

LP-184 is being studied in a first-in-human Phase 1 clinical trial, having been developed with guidance from Lantern’s AI Platform, RADR®, as a...

Lantern Pharma Receives IND Clearance from FDA Enabling Phase 1 Initiation for Drug Candidate LP-284 in Non-Hodgkin’s Lymphomas

This is the second IND Clearance over the last 100 days for drug candidates that are being developed using guidance from Lantern’s AI Platform...